Device Trial Radar · NCT07884994
HUGO-SLEEVE: Evaluating the Feasibility of Robotic Sleeve Gastrectomy With a New Platform
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medtronic
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Severe obesity is a chronic condition that can lead to a range of serious health problems. One common treatment option is sleeve gastrectomy, a weight-loss operation in which the size of the stomach is reduced. These procedures are increasingly being performed with the support of robotic surgical systems. However, there is still limited clinical experience with the Hugo™ Robotic-Assisted Surgery System for this type of operation. The aim of this study is to evaluate whether sleeve gastrectomy can be performed safely and reliably using the Hugo™ system. In particular, the study will assess whether the operation can be completed as planned with the robotic system and will examine outcomes during and after surgery. The study will include 50 adults with severe obesity who are scheduled to undergo sleeve gastrectomy. Information will be collected during the operation, including the duration of different surgical steps and the occurrence of any complications. Participants will be followed for six months after surgery. During this period, information on pain, complications, hospital stays, readmissions, and quality of life will be collected. The study aims to provide important information about the safe introduction and use of the Hugo™ system for this established weight-loss procedure.
Conditions
- Obesity (BMI > 35)
- Obesity (BMI > 35) and Diabetes Mellitus
- Obesity (BMI > 35) and Dyslipemia
- Obesity (BMI > 35) and High Blood Pressure
Interventions
Sleeve Gastrectomy using Hugo RAS platformDevice
Elective primary sleeve gastrectomy performed using the Hugo™ Robotic-Assisted Surgery (RAS) system, including the LigaSure™ RAS vessel-sealing system, in patients with obesity and a body mass index (BMI) ≥ 40 kg/m² or a BMI ≥ 35 kg/m² in combination with at least one obesity-related comorbidity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of robotic sleeve gastrectomy procedures successfully completed using the Hugo™ Robotic-Assisted Surgery (RAS) system including LigaSure™ RAS without intraoperative conversion to conventional laparoscopy or open surgery.Time frame: From beginning to the end of the Procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Medical Center Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.